Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Cancer: Clinical Characteristics and Outcomes [0.03%]
与胃癌相关的肺肿瘤血栓性微血管病的临床特征和结局
Tae-Se Kim,Soomin Ahn,Sung-A Chang et al.
Tae-Se Kim et al.
Purpose: Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal complication of gastric cancer (GC). This study aimed to evaluate the clinical characteristics, outcomes, and immunohistochemical profiles of patients ...
Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer [0.03%]
基线炎症负荷指数可预测HER2阴性晚期胃癌患者免疫检查点抑制剂联合化疗原发耐药
Tingting Wang,Huihui Zeng,Ting Hu et al.
Tingting Wang et al.
Purpose: Combinations of immune checkpoint inhibitors (ICIs) and chemotherapy have become the standard first-line treatment for human epidermal growth factor receptor 2 (HER-2)-negative advanced gastric cancer. However, p...
Jeesun Kim,Hyuk-Joon Lee
Jeesun Kim
Advances in gastric cancer screening have enabled earlier detection, shifting the focus of treatment toward preserving patients' quality of life (QoL). Function-preserving gastrectomy (FPG), including pylorus-preserving gastrectomy, proxima...
Updated Review of Proximal Gastrectomy for Gastric Cancer or Cancer of the Gastroesophageal Junction [0.03%]
近端胃切除术治疗胃癌或 gastroesophageal junction 恶性肿瘤的再评价研究
Tomoyuki Irino,Manabu Ohashi,Masaru Hayami et al.
Tomoyuki Irino et al.
Proximal gastrectomy (PG) has reemerged as a viable surgical option for managing proximal gastric cancer and gastroesophageal junction cancer, particularly for early-stage tumors, offering potential advantages over total gastrectomy (TG). T...
Management Strategy of Non-curative ESD in Gastric Cancer: Curative Criteria, and the Critical Building Block for Determining Beyond It [0.03%]
非治愈性ESD治疗胃癌的管理策略：治愈标准及其关键构成因素
Hyuk Lee
Hyuk Lee
Endoscopic submucosal dissection is performed in cases of early gastric cancer, where the risk of lymph node metastasis (LNM) is expected to be negligible, and 12%-21% of these patients are deemed to have undergone non-curative resections b...
Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers [0.03%]
胃癌的时空肿瘤异质性及预测生物标志物的不一致性
Hye Seung Lee
Hye Seung Lee
Gastric cancer (GC) is a highly heterogeneous disease that varies in both histological presentation and genetic characteristics. Recent advances in the treatment of metastatic and unresectable GC have made several biomarker tests essential ...
Yunjoo Cho,Soomin Ahn,Kyoung-Mee Kim
Yunjoo Cho
Combining chemotherapy with immune checkpoint inhibitors (ICIs) that target the programmed death-1 (PD-1) protein has been shown to be a clinically effective first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative ...
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update [0.03%]
全球胃癌治疗指南综合比较性评审：2024年更新版
Sang Soo Eom,Keun Won Ryu,Hye Sook Han et al.
Sang Soo Eom et al.
Differences in demographics, medical expertise, and patient healthcare resources across countries have led to significant variations in guidelines. In light of these differences, in this review, we aimed to explore and compare the most rece...
Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024 [0.03%]
第四届胃癌Kingca周专家共识会议：关于四期胃癌转化治疗的报告
Tae-Han Kim,Ichiro Uyama,Sun Young Rha et al.
Tae-Han Kim et al.
Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinical statements, the Korean Gastric Cancer...